LAFAYETTE, N.Y. — Ichor Life Sciences, based in LaFayette, has completed its acquisition of Woodland Biosciences, Inc. of Massachusetts.
The in-vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division, per a company news release.
The companies didn’t disclose any financial terms of this acquisition agreement.
(Sponsored)
The End of Non-Compete Agreements in New York?
Among the tidal wave of changes impacting employers, ranging from updated anti-harassment laws, restrictions on absenteeism policies and new pay transparency rules, New York is now poised to restrict the
Sales Employees are Not Always Exempt from Overtime
Are you sure that your company’s sales staff are properly categorized as exempt from the overtime requirements of the Fair Labor Standards Act (FLSA)? The FLSA regulations make it
Ichor Life Sciences describes itself as a preclinical contract-research organization offering services in discovery through pharmacology.
Ichor describes Woodland Biosciences as a preclinical contract-research organization. It was previously located on the campus of Tufts Veterinary Medicine School in North Grafton, Massachusetts.
Woodland’s research and development (R&D) facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette. Michael Briggs, the president of Woodland Biosciences, is now part of Ichor’s scientific leadership in pharmacology.
Briggs has “deep expertise and experience” in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others, Ichor said.
“Woodland Biosciences’ capabilities in developing orthotopic and syngeneic models with a focus on liver and pancreatic cancers, along with models in NASH and other metabolic diseases, expands the specialization within our Ichor Pharmacology group,” Kelsey Moody, CEO of Ichor Life Sciences, said. “As we seek to continuously add to our portfolio of services and broaden our expertise, we plan to identify other opportunities for acquisitions in the months ahead.”
